Preconditioning: From experimental findings to novel therapies in acute kidney injury

Minerva Urologica e Nefrologica

Volumn 61, Issue 3, 2009, Pages 143-157

  Shihab, F S ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Ischemia preconditioning; Kidney diseases; Treatment

Indexed keywords

4 ETHYL 2 HYDROXYIMINO 5 NITRO 3 HEXENAMIDE; ACETYLCYSTEINE; AMINOGUANIDINE; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CARBOLINE DERIVATIVE; CISPLATIN; CONTRAST MEDIUM; CYCLOSPORIN; DOPAMINE; ERYTHROPOIETIN; FINGOLIMOD; FUROSEMIDE; HEAT SHOCK PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE DONOR; NORPHENAZONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; XENON;

ACUTE DISEASE; BRAIN ISCHEMIA; CELL PROLIFERATION; CELL PROTECTION; DOSE RESPONSE; DRUG EFFECT; HEART MUSCLE ISCHEMIA; HEMORRHAGIC SHOCK; HUMAN; ISCHEMIA; ISCHEMIC PRECONDITIONING; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LIVER RESECTION; LOW DRUG DOSE; MORTALITY; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANIMALS; CALCINEURIN; ERYTHROPOIETIN; HUMANS; ISCHEMIC PRECONDITIONING; KIDNEY FAILURE, ACUTE; MESENCHYMAL STEM CELL TRANSPLANTATION;

EID: 74749093527     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Zimmerman B, Granger D. Mechanisms of reperfusion injury. Am J Med Sci 1994;307:284-92.
2. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1123-30.
3. Peralta C, Hotter G, Closa D, Gelpi E, Bulbena O, Rosello-Catafau J. Protective effect of preconditioning on the injury associated to hepatic ischemia-reperfusion in the rat: role of nitric oxide and adenosine. Hepatology 1997;25:934-7.
4. Sindram D, Rudinger HA, Upadhya AG, Strasberg SM, Clavien PA. Ischemic preconditioning protects against cold ischemic injury through an oxidative stress dependent mechanism. J Hepatol 2002;36:78-84.
5. Teoh N, Dela Pena A, Farrell G. Hepatic ischemic preconditioning in mice is associated with activation of NKkappaB, p38 kinase, and cell cycle entry. Hepatology 2002; 36:94-102.
6. + channels in cerebral ischemic preconditioning. Pharmacology 1996;92:4666-70.
7. Osborne DL, Aw TY, Cepinskas G, Kvietys PR. Development of ischemia/reperfusion tolerance in the rat small intestine. An epithelium-independent event. J Clin Invest 1994;94:1910-8.
8. Torras J, Herrero-Fresnadal, Lloberas N, Riera M, Cruzado J, Grinyo JM. Promising effects of ischemic preconditioning in renal transplantation. Kidney Int 2002;61:2218-27.
9. Zager RA, Baltes LA, Sharma HM, Jurkowitz MS. Responses of the ischemic acute renal failure kidney to additional ischemic events. Kidney Int 1984;26:689-700.
10. Zager RA, Iwata M, Burkhart KM, Schimpf BA. Post-ischemic acute renal failure protects proximal tubules from O2 deprivation injury, possibly by including uremia. Kidney Int 1994;45:1760-8.
11. Zager RA. Obstruction of proximal tubules initiates cytoresistance against hypoxic damage. Kidney Int 1995;47:628-37.
12. Park KM, Chen A, Bonventre JV. Prevention of kidney ischemia/reperfusion- induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemia pretreatment. J Biol Chem 2001;276:11870-6.
13. Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors. Am J Physiol Renal Physiol 2000;278: F380-7.
14. Jefayri MK, Grace PA, Mathie RT. Attenuation of reperfusion injury by renal ischaemic preconditioning: the role of nitric oxide. BJU Int 2000;85:1007-13.
15. Islam CF, Mathie RT, Dinneen MD, Kiely EA, Peters AM, Grace PA. Ischaemia-reperfusion injury in the rat: the effect of preconditioning. Br J Urol 1997;79:842-7.
16. Cochrane J, Williams BT, Banerjee A, Harken AH, Burke TJ, Cairns CB et al. Ischemic preconditioning attenuates functional, metabolic, and morphologic injury from ischemic acute renal failure in the rat. Ren Fail 1999;21:135-45.
17. Ambros JT, Herrero-Fresneda I, Borau OG, Boira JM. Ischemic preconditioning in solid organ transplantation: from experimental to clinics. Transplant Int 20:219-29.
18. Fuller TF, Freise CE, Feng S, Niemann CU. Ischemic preconditioning improves rat kidney graft function after ischemia/reperfusion injury. Transplant Proc 2005;37:377-8.
19. Behrends M, Walz MK, Kribben A, Neumann T, Helmchen U, Philipp T et al. No protection of the porcine kidney by ischaemic preconditioning. Exp Physiol 2000;85:819-27.
20. Kosieradzki M, Ametani M, Southard JH, Mangino MJ. Is ischemic preconditioning of the kidney clinically relevant? Surgery 2003;133:81-90.
21. Pasupathy S, Homer-Vanniassinkam S. Ischaemic preconditioning protects against ischaemia/reperfusion injury: emerging concepts. Eur J Vasc Endovasc Surg 2005;29:106-15.
22. Bonventre JV. Kidney ischemic preconditioning. Curr Opin Nephrol Hypertens 2002;11:43-8.
23. Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: from adenosine receptor of KATP channel. Annu Rev Physiol 2000;62:79-109.
24. Valhaus C, Shulz R, Post H, Rose J, Heusch G. Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. J Mol Cell Cardiol 1998;30:197-209.
25. Weinbrenner C, Liu GS, Cohen MV, Downey JM. Phodsphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J Mol Cell Cardiol 1997;29:2383-91.
26. Garlid KD, Dos SP, Xie ZJ, Costa AD, Paucek P. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K(+) channel in cardiac function and cardioprotection. Biochim Biophys Acta 2003;1606:1-21.
27. Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Cir Res 1993;72:1293-9.
28. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893-9.
29. Ates E, Genc E, Erkasap N, Erkasap S, Akman S, Firat P et al. Renal protection by brief liver ischemia in rats. Transplantation 2002;74:1247-51.
30. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief ischemia in noncardiac tissue. Circulation 1996;94:2193-200.
31. Addison PD, Neligan PC, Ashrafpour H, Khan A, Zhong A, Moses M et al. Noninvasive remote ischemic preconditioning for global protection of skeletal muscle against infarction. Am J Physiol Heart Circ Physiol 2003;285:H1435-43.
32. Reutzel-Selke A, Pratschke J, Martins PN, Denecke C, Jurisch A, Kotsch K et al. Ischemic preconditioning produces systemic protective and adoptively transferable effects. Kidney Int 2008;74:622-30.
33. Liem DA, Verdouw PD, Ploeg H, Kazim S, Duncker DJ. Sites of action of adenosine in interorgan preconditioning of the heart. Am J Physiol Heart Circ Physiol 20O2;283:H29-37.
34. Hochachka PW. Defense strategies against hypoxia and hypothermia. Science 1986;231:234-41.
35. Stenzel-Poore MP, Stevens SL, Xiong Z, Lessov NS, Harrington CA, Mori M et al. Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. Lancet 2003;362:1028-37.
36. Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 1990;66:913-31.
37. Pang CY, Yang RZ, Zhong A, Xu N, Boyd B, Forrest CR. Acute ischaemic preconditioning protects against skeletal muscle infarction in the pig. Cardiovasc Res 1995;29:782-8.
38. Peralta C, Bartrons R, Riera L, Manzano A, Xaus C, Gelpi E et al. Hepatic preconditioning preserves energy metabolism during sustained ischemia. Am J Physiol Gastrointest Liver Physiol 2000;279:G163-71.
39. Arai M, Thurman RG, Lemasters JJ. Contribution of adenosine A(2) receptors and cyclic adenosine monophosphate to protective ischemic preconditioning of sinusoidal endothelial cells against Storage/ Reperfusion injury in rat livers. Hepatology 2000;32:297-302.
40. Pucar D, Dzeja PP, Bast P, Juranic N, Macura S, Terzic A. Cellular energetics in the preconditioned state: protective role for phosphotransfer reactions captured by 18O-assisted 31P NMR. J Biol Chem 2001;276:44812-9.
41. Carini R, De Cesaris MG, Splendore R, Bagnati M, Albano E. Ischemic preconditioning reduces Na(+) accumulation and cell killing in isolated rat hepatocytes exposed to hypoxia. Hepatology 2000;31:166-72.
42. Wang L, Cherednichenko G, Hernandez L, Halow J, Camacho SA, Figueredo V et al. Preconditioning limits mitochondrial Ca(2+) during ischemia in rat hearts: role of K(ATP) channels. Am J Physiol Heart Circ Physiol 2001;280:H2321-8.
43. Funaki H, Shimizu K, Harada S, Tsuyama H, Fushida S, Tani T et al. Essential role for nuclear factor kappaB in ischemic preconditioning for ischemia-reperfusion injury of the mouse liver. Transplantation 2002;74:551-6.
44. Teoh N, Dela PA, Farrell G. Hepatic ischemic preconditioning in mice is associated with activation of NKkappaB, p38 kinase, and cell cycle entry. Hepatology 2002;36:94-102.
45. Mestril R, Chi SH, Sayen MR.O'Reilly K, Dillmann WH. Expression of inducible stress protein 70 in rat heart myogenic cells confers protection against simulated ischemia-induced injury. J Clin Invest 1994;93:759-67.
46. Plumier JC, Ross BM, Currie RW, Angelidis CE, Kazlaris H, Kollias G et al. Transgenic mice expressing the human heat shock protein 70 have improved postischemic myocardial recovery. J Clin Invest 1995;95: 1854-60.
47. Wagner M, Cadteg P, Ruf R, Mazzucchelli L, Ferrari P, Redaelli CA. Heme oxygenase-1 attenuates ischemia/ reperfusion-induced apoptosis and improves survival in rat renal allografts. Kidney Int 2003;63:1564-73.
48. Franco-Gou R, Rosello-Catafau J, Castillas-Ramirez A, Massip-Salcedo M, Rimola A, Calvo N et al. How ischemic preconditioning protects small liver grafts. J Pathol 2006;208:62-73.
49. Lai IR, Chang KJ, Chen CF, Tsai HW. Transient limb ischemia induces remote preconditioning in liver among rats: the protective role of heme oxygenase-1. Transplantation 2007;83:363-4.
50. Burne-Taney MJ, Liu M, Baldwin WM, Racusen L, Rabb H. Decreased capacity of immune cells to cause tissue injury mediates kidney ischemic preconditioning. J Immunol 2006;176:7015-20.
51. Fernanadez L, Heredia N, Grande L, Gomez G, Rimola A, Marco A et al. Preconditioning protects liver and lung damage in rat liver transplantation: role of xanthine/xanthine oxidase. Hepatology 2002;36: 562-72.
52. Papanastasiou S, Estdale SE, Homer-Vanniasinkam S, Mathrie RT. Protective effect of preconditioning and adenosine pretreatment in experimental skeletal muscle reperfusion injury. Br J Surg 1999;86:916-22.
53. Sola A, Hotter G, Prats N, Xaus C, Gelpi E, Rosello-Catafau J. Modification of oxidative stress in response to intestinal preconditioning. Transplantation 2000;69:767-72.
54. Yadav SS, Sindram M, Perry DK, Clavien PA. Ischemic preconditioning protects the mouse liver by inhibition of apoptosis through a caspase-dependent pathway. Hepatology 1999;30:1223-31.
55. Chien CT, Chen CF, Hsu SM, Lee PH, Lai MK. Protective mechanism of preconditioning hypoxia attenuates apoptosis formation during renal ischemia/reperfusion phase. Transplant Proc 1999;31:2012-3.
56. Cinel I, Avaln D, Cinel L, Polat G, Atici S, Mavioglu I et al. Ischemic preconditioning reduces intestinal epithelial apoptosis in rats. Shock 2003;19:588-92.
57. Clavien PA, Yadav S, Sindram D, Bentley RC. Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans. Ann Surg 2000;232:155-62.
58. Kim GT, Chun YS, Park JW, Kim MS. Role of apoptosis-inducing factor in myocardial cell death by ischemia-reperfusion. Biochem Biophys Res Commun 2003;309:619-24.
59. Kharbanda RK, Peters M, Walton B, Kattenhorn M, Mullen M, Klein N et al. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia reperfusion in human in vivo. Circulation 2001;103:1624-30.
60. Jerome SN, Akimitsu T, Gute DC, Korthuis RJ. Ischemic preconditioning attenuates capillary no-reflow induced by prolonged ischemia and reperfusion. Am J Physiol 1995;268:H2063-7.
61. Jenkins DP, Pugsley WB, Alkhulaifi AM, Kemp M, Hooper J, Yellon DM. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart 1997;77:314-8.
62. Li G, Chen S, Luo W. Cardiac ischemic preconditioning improves lung preservation in valve replacement operations. Ann Thorac Surg 2001;71:631-5.
63. Clavien PA, Selzner M, Rudiger HA, Graf R, Kadry Z, Rousson V et al. A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg 2003;238:843-50.
64. Amador A, Grande L, Marti J, Deulofeu R, Miquel R, Sola A et al. Ischemic pre-conditioning in deceased donor liver transplantation: a prospective randomized clinical trial. Am J Transplant 2007;7:2180-9.
65. Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002;106:2881-3.
66. Sitzer M, Foerch C, Neumann-Haefelin T, Steinmetz H, Misselwitz B, Kugler C et al. Transient ischaemic preceding anterior circulation infarction is independently associated with favourable outcome. J Neurol Neurosurg Psychiatry 2004;75:659-60.
67. Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akhtar AM et al. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation 2007;116:198-105.
68. Bernhardt WM, Eckardt KU. Physiological basis for the use of erythropoietin in critically ill patients at risk for acute kidney injury. Curr Opin Crit Care 2008;14:621-6.
69. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999;55:808-20.
70. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M et al. Eryhtropoietin mediates tissue protection through an erythropoietin and common beta-sub-unit heteroreceptor. Proc Natl Acad Sci U S A 2004;101:14907-12.
71. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004;103:921-6.
72. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnatto A et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971-5.
73. Bahlman FH, Fliser D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 2009;18:15-20.
74. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001;98:4044-9.
75. Sharpies EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004;15:2115-24.
76. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbapoietin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006;69:1806-13.
77. Mitra A, Bansal S, Wang W, Falk S, Zolty E, Schrier RW. Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol Dial Transplant 2007;22:2349-53.
78. Abdelrahman M, Sharpies EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004;22:63-9.
79. Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le Nahour G et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 2001;16:932-8.
80. Goldfarb M, Rosenberger C, Ahuva S, Rosen S, Heyman SN. A role for erythropoietin in the attenuation of radio-contrast-induced acute renal failure in rats. Ren Fail 2006;28:345-50.
81. Imamura R, Isaka Y, Ichimaru N, Takahara S, Okuyama A. Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. Biochem Biophys Res Commun 2007;353:786-92.
82. Yokomaku Y, Sugimoto T, Kume S, Araki S, Isshiki K, Chin-Kanasaki M et al. Asialoerythropoietin prevents contrast-induced nephropathy. J Am Soc Nephrol 2008;19:321-8.
83. Lindenblatt N, Menger MD, Klar E, Vollmar B. Darbapoietin-alpha does nor promote microvascular thrombus formation in mice: role of eNOS-dependent protection through platelet and endothelial cell deactivation. Arterioscler Thromb Vasc Biol 2007;27:1191-8.
84. Humphreys BD, Bonventre JV. Mesenchymal stem cells in acute kidney injury. Annu Rev Med 2008;59: 311-25.
85. Bussolati B, Tetta C, Camussi G. Contribution of stem cells to kidney repair. Am J Nephrol 2008;28:813-22.
86. Togel F, Isaac J, Hu Z, Weiss K, Westenfelder C. Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney Int 2005;67:1772-84.
87. Drexler H, Meyer GP, Wollen KC. Bone-marrow-derived cell transfer after ST-elevation myocardial infarction: lessons from the BOOST trial. Nat Clin Pract Cardiovasc Med 3:S65-8.
88. Sakr M, Zetti G, Hassanein TI, Farghali H, Nalesnik MA, Gavaler JS et al. FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. Hepatology 1991;13:947-51.
89. Sakr M, Zetti G, McClain C, Gavaler J, Nalesnik M, Todo S et al. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. Transplantation 1992;53:987-91.
90. Yuan CM, Bohen EM, Musio F, Carome MA. Sublethal heat shock and cyclosporine exposure produces tolerance against subsequent cyclosporine toxicity. Am J Physiol 1996;271:F571-8.
91. Yang CW, Ahn HJ, Han HJ, Kim WY, Li C, Shin MJ et al. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/ reperfusion injury in rat kidney. Transplantation 2001;72:1753-9.
92. Shihab FS, Bennett WM, Andoh TF. Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. Transplantation 2009;87:326-9.
93. Valentin JF, Bruijn JA, Paul LC. Donor pretreatment with mycophenolate mofetil. Protection against ischemia-reperfusion injury in the rat. Transplantation 2000;69:327-8.
94. Awad AS, Ye H, Huang L, Li L, Foss FWJr, Macdonald TL, Lynch KR et al. Selective sphyngosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol 2006;290:F1516-24.
95. Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007;376:1-43.
96. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 2008;3:281-7.
97. Yamasowa H, Shimizu S, Inoue T, Takaoka M, Matsumura Y. Endothelial nitric oxide contributes to the renal protective effects of ischemic preconditioning. J Pharmacol Exp Ther 2005;312:153-9.
98. Nakajima A, Ueda K, Takaoka M, Yoshimi Y, Matsumura Y. Opposite effects of pre- and postis-chemic treatments with nitric oxide donor on ischemia/reperfusion-induced renal injury. J Pharmacol Exp Ther 2006;316:1038-46.
99. Bertelli AA, Migliori M, Panichi V, Origlia N, Filippi C, Das DK et al. Resveratrol, a component of wine and grapes, in the prevention of kidney disease. Ann N Y Acad Sci 2002;957:230-8.
100. Ma D, Lim T, Xu J, Tang H, Wan Y, Zhao H et al. Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1α activation. J Am Soc Nephrol 2009;20:713-20.